Clinical trials have begun after preclinical studies demonstrated the efficacy of small molecule inhibitors against mutant forms of IDH1 and IDH2 accompanied by a reduction of (R)-2-HG levels, which resulted in a block of de-differentiation and growth suppression of AML tumor cells [29, 54]. This evidence concerns the gene IDH1 and neoplasm.